Craft

Silverback Therapeutics

Stock Price

$5.9

2022-11-08

Market Capitalization

$206.2 M

2022-11-08

Silverback Therapeutics Summary

Company Summary

Overview
Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases. It uses ImmunoTAC technology to create therapeutic molecules that can be systemically administered to patients and act only at the sites of disease, sparing healthy tissues from unwanted side effects
Type
Public
Status
Active
Founded
2016
HQ
Seattle, WA, US | view all locations
Website
https://silverbacktx.com/
Cybersecurity rating
Sectors

Key People

  • Laura Shawver
  • Naomi Hunder

    Naomi Hunder, Chief Medical Officer

  • Russ Hawkinson

    Russ Hawkinson, Senior Vice President of Finance

  • Valerie Odegard

    Valerie Odegard, President & Chief Scientific Officer

Operating MetricsView all

Lead Optimization Stage Products

1

Q3, 2020

IND-Enabling Stage Products

1

Q3, 2020

Phase I Trials Products

1

Q3, 2020

LocationsView all

1 location detected

  • Seattle, WA HQ

    United States

    500 Fairview Ave N #600

Silverback Therapeutics Financials

Summary Financials

Net income (Q3, 2022)
($17.9M)
Cash (Q3, 2022)
$203.2M
EBIT (Q3, 2022)
($18.9M)
Enterprise value
$3.2M

Footer menu